Skip Ribbon Commands
Skip to main content
Navigate Up

Therapeutics

Listed below are brief descriptions of the CAMH therapeutics that are available for licensing. Follow the links to read a non-confidential summary of each technology. 
 
Feel free to contact our office should you require more information or wish inquire about the first steps in securing a licensing deal.
 

 

Brief Description: CAMH scientists have   identified an interaction between dopamine transporter DAT and the presynaptic dopamine type 2 receptor (D2) which is thought to be an underlying cause for Attention Deficit Hyperactivity Disorder (ADHD). By characterizing this interaction, our scientists have developed a peptide that interferes with this coupling. As a result, this interfering peptide could lead to the development of a breakthrough therapy capable of delivering enhanced affinity, better efficacy, and a superior side-effect profile. Click here to read more. 

Brief Description: Our scientists have identified a protein‐protein coupling between the glutamate R2 (GluR2) ‐ α‐amino‐3‐hydroxy‐5‐methylisoxazole‐4‐propionic acid (AMPA) receptor and the extracellular protein glyceraldehyde‐3‐phosphate dehydrogenase (GAPDH) as a novel target for the treatment of the neurodegenerative effects of multiple sclerosis (MS). By characterizing the protein‐protein (GluR2‐GAPDH complex) interaction we have developed a peptide that interferes with this coupling thereby leading to the development of a breakthrough therapy capable of delivering enhanced affinity, efficacy, and a superior side effect profile. Click here to read more.
Brief Description: Our researchers have discovered that two key proteins, the dopamine D2 receptor (D2R) and the protein “disrupted in schizophrenia 1” (DISC1), form a protein‐protein interaction complex which has been shown to contribute to the pathophysiology of schizophrenia. Through the characterization of the protein‐protein interaction, we have developed a peptide that specifically interferes with this coupling; leading to the development of a breakthrough therapy capable of delivering enhanced affinity, efficacy, and a superior side effect profile. Click here to read more.
 
Brief Description: Our scientists have identified a previously unrecognized molecular pathway involving a series of protein‐protein interactions that underlies glutamate (GluR2) containing - α‐amino‐3‐hydroxy‐5‐methylisoxazole‐4‐propionic acid (AMPA) receptor mediated excitotoxicity as a novel target for treatment of stroke induced neuronal death and brain damage. Using this knowledge, CAMH scientists have discovered an interfering peptide which protects cells against ischemic- induced stroke, increasing neuronal survival and total infarct volume for up to 6 hours post administration. Click here​ to read more. 
​​​​​
 

 Contact Us

 
For more information, contact:
Dr. Klara Vichnevetski​
Director, Industry Partnerships and Technology Transfer
tech.transfer@camh.ca ​
(416) 535-8501 ext. 6056​
CAMH Switchboard 416-535-8501
CAMH General Information Toronto: 416-595-6111 Toll Free: 1-800-463-6273
Connex Ontario Help Lines
Queen St.
1001 Queen St. W
Toronto, ON
M6J 1H4
Russell St.
33 Russell St.
Toronto, ON
M5S 2S1
College St.
250 College St.
Toronto, ON
M5T 1R8
Ten offices across Ontario